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Introduction 
The idea of replacing body parts has attracted interest for a long 
time. In the third century, legend holds that St Cosmas and St 
Damian succeeded in grafting a leg from a recently deceased 
Ethiopian to replace onto the body of a patient. Unfortunately, 
this has not proved to be repeatable – the fact that the 
laboratory assistants in many representations of this event have 
wings indicating that a celestial connection may be required to 
make the operation more likely to succeed. 
The more recent idea that it may be possible to take skin from 
a living person and, using the technique of cloning or nuclear 
transfer, make a replacement brain or heart is the focus of this 
Oration. Fig 1 illustrates the concept: the nucleus of a skin cell 
from the patient is transferred to an enucleated egg which forms 
an embryo. Embryonic stem cells (ESCs) can be derived from 
such an embryo and then directed into any tissue or organ 
desired. This theoretical scheme would give people new cells of 
their own genetic constitution, thereby avoiding problems of 
immunological rejection. This is an indication of the direction 
in which current research is moving at an encouraging pace.
The history of somatic cell nuclear transfer to eggs
Pioneering the principle: the work of Briggs and King
In the 1950s it was not known whether all cells of the body have 
the same genes. Subsequent work has shown that almost all cells 
of the body do in fact have the same genome. If this had not 
been the case, the production of replacement cells of one kind 
from available cells of an entirely different kind could never 
have been achieved. A reasonable proposition in the 1890s by 
August Weismann (1834–1914) was that, as cells differentiate 
during development, the new cell types form as a result of 
either the lack, or the permanent inactivation, of those genes no 
longer needed for a particular lineage.1 For example, skin cells 
might permanently lose the function of genes needed for the 
nervous system. In support of this concept, we now know that 
the process of cell differentiation is remarkably stable. Cells of 
one kind in the body almost never seem to switch directly into 
a completely unrelated cell type. Therefore an important aspect 
of the normal process of cell differentiation is that, as soon as a 
cell has embarked on a fi nal type of differentiation, this status 
almost never changes. 
However, this characteristic of stable cell differentiation can 
be reversed by ‘nuclear transfer’. The basis of this experimental 
procedure is to suck a cell into a fi ne micropipette such 
that the cell’s wall is broken but the nucleus remains intact. 
This ruptured cell and intact nucleus is then injected into 
an unfertilised egg whose own chromosomes have been 
removed or destroyed by ultraviolet irradiation. This egg then 
begins development using the implanted nucleus in place of 
the egg and sperm nuclei which would normally be present 
after fertilisation. In some cases this transplanted nucleus in 
combination with the egg cytoplasm can develop into a normal 
adult animal (Fig 1). This procedure was pioneered by Briggs 
and King in 1952.2 However, the results they obtained at that 
time did not yield normal development from the nucleus of a 
specialised cell and therefore appeared to support the idea of 
Weissmann.
Early work with Xenopus
I was encouraged by my supervisor, Michail Fischberg, a 
lecturer at Oxford, to try to apply the technology developed 
by Briggs and King to the South African frog Xenopus. 
This was because Xenopus had enormous advantages for 
laboratory work over Rana pipiens, the species used by Briggs 
and King. Xenopus embryos can be grown to sexual maturity 
within a year and, being permanently aquatic, the animals 
can be kept in easily cleaned tanks of water rather than in a 
terrarium. But it was easier said than done. First, the Xenopus 
egg is surrounded by a thick layer of jelly that is totally 
impenetrable even with the sharpest of needles (Fig 2). 
By good luck my supervisor had recently bought a new ultra-
violet microscope light source. We found that the ultra-violet 
emission of this source included a very low wavelength of 
light, which happened to dissolve the jelly of the Xenopus 
egg. Very conveniently, another wavelength of emission 
from this source destroyed DNA and therefore permitted 
the destruction of the chromosomes of the unfertilised egg. 
This UV-irradiation was much easier and more reliable than 
trying to remove the chromosomes in the unfertilised egg by 
micromanipulation. Even with the benefi t of jelly depletion 
by ultraviolet light, it was necessary to make an extremely 
sharp needle with an unconstricted opening. Eventually a 
way was found of creating such a needle in glass, using a 
microforge that I made, so that it could gently rupture a cell 
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but not the nucleus and yet contain a sharp enough point not 
to damage the recipient egg (Fig 3).
Another piece of good fortune resulted from the wisdom 
of my supervisor. He had a student whose project involved 
studying the nucleolus of these amphibian cells. The project 
involved killing the egg nucleus of a fertilised egg to create 
haploid embryos, recognisable by having only one nucleolus 
in their cells (diploid embryos have two nucleoli per nucleus); 
haploid embryos always die before becoming a swimming 
tadpole. The student reported that she had obtained one-
nucleolated embryos which survived entirely normally. Wisely 
my supervisor said to the student, ‘you must fi nd the actual frog 
which gave you this extraordinary result.’ Very surprisingly, 
the frog concerned was a natural mutation in which all its cells 
Fig 2. Xenopus egg. The egg is surrounded by a thick layer of jelly that is 
impenetrable by needles.
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had a single nucleolus instead of the normal two for a diploid 
embryo; it had lost all ribosomal genes on one chromosome set. 
The really important point was that this immediately provided 
an invaluable genetic marker for nuclear transfer experiments. 
Without this, the experiments I did would probably have never 
been believed. 
Within a couple of years of starting graduate work, I was 
fortunate that I had been able to obtain entirely normal embryo 
development from the transplanted nucleus of a feeding 
tadpole’s intestinal epithelium (Fig 4). In the course of time, 
some of these embryos developed into sexually mature adult 
animals. They therefore proved that the nucleus of an intestine 
cell can form every cell type in the body and therefore that the 
process of differentiation cannot involve the loss or permanent 
inactivation of any genes.3 This conclusion differed from that 
of Briggs and King and, thanks to the use of the genetic nuclear 
marker, was in time accepted by the scientifi c community. 
From amphibians to mammals
In the early 1960s, a journalist asked me whether this kind of 
work could ever succeed in mammals or even in humans. I 
said that I had no idea, but guessed that anything from 10–100 
years might be necessary for this to be achieved. It turned out 
to be a good guess because it was actually 45 years later that 
the fi rst successful somatic cell nuclear transplantation to 
mammalian eggs was reported, resulting in Dolly the sheep. 
In the end, the experimental design used to create Dolly was 
the same as that used for the Xenopus frog work. The problem 
was that many of those who had tried to repeat the amphibian 
experiments with mammals failed to use exactly the same 
procedure. 
Nowadays we know that most kinds of mammals can be 
cloned using somatic cell nuclear transfer to eggs. Each species 
has particular characteristics often requiring a large amount of 
work to discover ways of overcoming these obstacles. Recently 
there has been success in nuclear transfer in humans, though it 
is not permitted to grow the embryos obtained into advanced 
embryos or fetuses. In mice, this nuclear transfer procedure 
has been refi ned to an extraordinary extent. Dr Wakayama, 
in Japan, has even succeeded in carrying out a serial nuclear 
transfer experiment.4 He transplanted the nucleus of a cumulus 
cell to a mouse egg and grew that embryo to an adult. He then 
took a cumulus cell from that mouse and transplanted its 
nucleus back to another egg. In the end, he did this 25 times. 
Therefore the original transplanted nucleus had undergone 
some 500 cell divisions, much more than any cell would ever 
do in the whole life of a mouse or human. Nevertheless, that 
nucleus retained its totipotentiality and never underwent any 
kind of death or became cancerous (Fig 5). In this way the egg 
can be seen to immortalise the nucleus of a specialised cell, 
and therefore provide a source of rejuvenated embryo cells 
indefi nitely. 
The work discussed above leads to two fundamental 
conclusions. One is that as cells undergo normal differentiation 
from an embryo to an adult, almost all cells retain a complete 
and intact genome; no genes are lost or permanently 
inactivated. Second, an egg has the ability to rejuvenate the 
nucleus of a specialised cell so that it can create cells which 
have gone back in development to an embryonic state and can 
therefore, in principle, be a source of rejuvenated cells for cell 
replacement.
Basic principles of cell differentiation
Having said that nuclear transfer to eggs can fully reprogramme 
the nucleus of an adult cell, this does not always happen. In fact, 
when starting from a specialised cell, the success with which the 
transplanted nucleus from that cell can, in combination with 
Fig 4. Intestinal tract of feeding tadpole (GFP marked).
Fig 5. Serial nuclear transplantation. Wakayama et al (2013)4 demonstrated 25 generations of serial nuclear transfer, with 500 cell divisions from the 
ﬁ rst donor nucleus. No cancer incidence was observed.
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an enucleated egg, form an entirely normal, sexually mature 
individual is only about 1 or 2%. Most embryos formed in this 
kind of experiment develop abnormally and do not reach the 
adult stage. The question therefore arises as to how, in normal 
development, new kinds of cells arise, all starting from a single, 
fertilised egg cell.
There are two fundamental principles by which this is achieved 
(Fig 6). The fi rst principle is that as a fertilised egg divides 
into its daughter cells, some of the components of the egg are 
asymmetrically distributed to the two daughter cells, causing 
the daughter cells and their progeny to specialise in different 
directions. This process of the asymmetric distribution of 
parental cell components continues through much of life. This is 
particularly clear in the case of the invertebrate nervous system. 
Typically, a parental mother cell divides into two unequally 
sized daughters. The smaller daughter acquires a very high 
concentration of components from one part of the mother 
cell. The other larger daughter has a much lower concentration 
of these components. As a result the small cell with the high 
concentration of components specialises into a mature nerve 
cell. The other cell typically remains as a ‘stem cell’ and then 
makes further asymmetric divisions (Fig 7). 
The other principle is that cells of one kind frequently signal 
to cells of another. They release protein factors which activate 
selected genes. These factors, often referred to as growth 
factors, cause the cells that receive them to change their course 
of differentiation and make a new cell type. Signalling in 
this way is a very common characteristic of normal embryo 
development. 
Signalling from one cell to another often takes place in a 
concentration-dependent way. The signal factors released 
by one cell become diluted as they spread through an 
increasingly distant set of receiving cells. Importantly, it is the 
concentration of these factors that ultimately decides the fate of 
the responding cells. Those receiving a high concentration will 
differentiate in one direction, for example becoming muscle, 
whereas those receiving a lower concentration at the same time 
will specialise in another way, becoming skin or brain. This 
principle of a morphogen gradient commonly accompanies 
signalling and so increases the range of cell types that can be 
formed by a single signalling event (Fig 8).
As a result of these two processes acting in combination, the 
whole range of specialised cell types is formed. Once formed, 
as has been said, the specialised state of these cells continues 
for life. 
A further variant of signalling between cells has been 
discovered: in what is termed the ‘community effect’, the 
absolute concentration of signalling factor can be built up so 
long as a large number of cells each contribute to it. These 
cells have to be in close proximity to each other. Distant cells 
separated by many other non-contributing cells would never 
provide a suffi cient concentration of signalling factor to be 
Fig 6. Mechanisms of cell dif-
ferentiation. The ﬁ rst mechanism is 
asymmetric distribution of deter-
minants in the egg, giving rise to an 
asymmetric distribution of cells in 
the embryo. Subsequently, signalling 
between cells (red arrows) causes 
further differentiation to give the ec-
toderm, mesoderm and endoderm.
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Fig 7. Formation of specialised cells from stem cells. Gene activation molecules accumulate in the stem cell and move to one side in response to an 
external signal. Asymmetric cell division gives rise to a specialised skin cell and depends on the concentration of transcription factors (red spots).
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effective. This mechanism seems to be important when a large 
number of cells need to differentiate in the same direction. 
Interestingly, the same basic principle, ‘quorum sensing’, was 
discovered in bacteria which create fl uorescent light in the 
light organ of certain fi sh. Only when the bacteria achieve a 
suffi ciently high concentration do they cause the light organ to 
emit light and hence act as a bait to attract freshwater animals 
so that they can serve as a source of food for the fi sh. It is 
interesting that the same fundamental principle can emerge 
from two completely unrelated kinds of work.
The mechanisms behind nuclear transfer
Meiotic oocytes and nuclear reprogramming
It generally turns out that if a new procedure achieves 
something useful it is valuable to understand its mechanism. 
Thus it would be scientifi cally interesting and of potential 
practical value to identify the reprogramming components 
of an amphibian egg. An obvious idea is to separate out the 
components of eggs and see whether they can reprogramme 
nuclei in a test tube. However, this has never proved a 
successful approach to studying mechanisms of gene 
transcription. It therefore seemed worth trying a lateral 
approach, as exemplifi ed by the story of the discovery of 
nerve growth factor by Cohen and Levi-Montalcini, who 
received their Nobel Prize for this work in 1986.5 They had 
been struggling for a long time to analyse the material in 
a hen’s egg that can induce massive nerve growth, using 
a phosphodisesterase enzyme obtained from a very rare 
moccasin snake. However, on discovering that the world’s 
supply of moccasin snakes was insuffi cient for them to fi nish 
their experiments, they had the clever idea that snake venom 
might be closely related to the products of salivary glands 
of mice and rats. So they forgot about moccasin snakes and 
worked with rat salivary glands, which also seemed to have 
phosphodiesterase activity, and succeeded in identifying the 
nerve growth factor. The principle here seems to be that if you 
are struggling with diffi cult material it always pays to see if 
some readily obtainable alternative will work as well.
We followed this principle in trying to identify the 
reprogramming components of eggs. We were hampered by 
the fact that most somatic nuclei, which divide very slowly, 
undergo extensive chromosome loss and damage when 
transplanted to eggs due to the very fast rate of replication 
imposed by the egg on somatic nuclei. We needed an assay 
which tested transcription (RNA synthesis) rather than DNA 
replication, and chose to test the growing oocyte of an ovary 
in fi rst meiotic prophase as an alternative to an egg. We found 
that we could inject multiple somatic nuclei into the specialised 
nucleus (germinal vesicle) of the oocyte, which is a natural 
egg progenitor. Remarkably, the injected nuclei were rapidly 
reprogrammed to start expressing pluripotency genes which 
are not expressed in adult cells. This effect was seen in a very 
high percentage of injected nuclei. Furthermore, we found that 
the somatic nuclei of mammalian cells worked just as well as 
those of frog cells. The so-called germinal vesicle of an oocyte 
has a very high concentration of developmentally important 
components, since the germinal vesicle contents are normally 
dispersed into the naturally fertilised egg and are necessary for 
normal development. This gave us an invaluable test system 
to identify the reprogramming components of an egg that are 
directly derived from the germinal vesicle of an oocyte. 
It is interesting that if you incubate somatic nuclei in 
extracts of eggs or oocytes they do not undergo any signifi cant 
transcription. If, however, you inject multiple nuclei into a 
living oocyte, transcription is re-initiated several hundred 
times in a day. This gives an invaluable test system for 
factors affecting transcription and reprogramming. A key 
characteristic of an oocyte is that, unlike an egg, it never 
induces DNA replication of transplanted nuclei, and so causes 
no chromosome damage. 
As a result of numerous experiments, we have some idea 
of the sequence of events that leads to the reprogramming 
of a transplanted somatic nucleus. As seen in Fig 9, the fi rst 
crucial event is an invasion of the transplanted somatic nuclei 
by a specialised oocyte-specifi c linker histone. This happens 
within a few hours of nuclear transfer and is a necessary step 
towards the induced transcription of pluripotency stem-cell-
like genes. Soon after this, another histone variant, namely 
H3.3, displaces the linker histone and opens up the previously 
quiescent genes for transcription by RNA polymerase II. 
There are no doubt many other steps to be discovered. But the 
general principle seems to be that the oocyte is endowed with 
a very high concentration of the components that can turn a 
somatic nucleus back from its adult state into an embryonic 
one. These same components are almost certainly active in the 
newly fertilised egg when they have to decondense and activate 
Fig 8. Cells specialise in ways determined by the concentration of 
morphogen molecules (pink circles) that come from the source and 
reach  distant cells by diffusion.
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(reprogramme) the highly specialised sperm nucleus after 
fertilisation.
Overcoming resistance to reprogramming
The next major question in this fi eld asks why the 
reprogramming components of an egg do not work successfully 
in all somatic nuclei transplanted to them. This is evidently 
due to a strong resistance of the somatic nucleus towards 
being reprogrammed by an egg. As we have said, somatic cells 
are extremely stable in their differentiation and would never 
normally be reprogrammed by an egg in the way that a sperm 
is. The egg does a rather good job of reprogramming many 
of the quiescent genes introduced with a somatic nucleus 
but cannot do it perfectly. We need to know the basis of this 
resistance and hence stability of differentiation. Using the 
oocyte assay we can progressively remove components from 
the transplanted nuclei to fi nd out which components are 
important in giving this stable resistance to reprogramming.
We now know some of the most important stabilising 
components. One of these is the methylation of DNA in a 
somatic nucleus; the nucleus strongly resists demethylation 
by an oocyte. Another key factor is modifi cation of the 
histones that are wrapped up with the DNA in somatic 
nucleosomes. An example of this is histone H2A lysine 27 
trimethylation. In other cases, we fi nd that a combination of 
several different histone modifi cations is required. Gradually 
we are discovering which histone modifi cations are important 
(such as the ubiquitination of histone H2A) and how they 
can resist reprogramming, often in combination. Looking 
further ahead, it seems that the spacing of nucleosomes 
between genes may also be so arranged that it is diffi cult for 
egg cytoplasmic components to rearrange these. In the long 
term it should be possible to identify most or even all of the 
resistance-inducing components of a somatic nucleus and 
then remove them or cancel their effect. In the end this might 
make it possible to reprogramme somatic nuclei with very 
high effi ciency. This could prove particularly valuable when we 
discuss the spectacular advances now made in the induction of 
pluripotency of stem cells.
Induced pluripotency
Some of the great discoveries in biomedical science have come 
completely unexpectedly. No one would have predicted the 
discovery, in 1981, by Martin Evans that permanent cultures of 
embryonic cells could be made.6 Evans discovered that certain 
cells taken from a strain of mice could be placed in culture 
under specifi ed conditions and that these cells would proliferate 
indefi nitely without proceeding, as embryonic cells usually do, 
to various kinds of differentiation. Even more impressively, 
under particular culture conditions these cells could be induced 
to differentiate into specialised cells of desired kinds. 
As long ago as the 1980s, Weintraub and colleagues were 
able, through an ingenious design, to isolate a particular 
transcription factor which they named MyoD. They then 
overexpressed this protein in a range of different kinds of cells 
and found, remarkably, that in many cases this factor could 
induce cells to become muscle, even if the cells were not muscle 
related in their differentiation state.7 This established the 
fundamental principle that the massive overexpression of a new 
factor can, in many cases, transform a cell, or at least some of its 
daughter cells, so that they follow a pathway of differentiation 
related to that of the transcription factor. 
For a long time MyoD was the only demonstrated example 
of this principle. However, in 2006, Takahashi and Yamanaka 
announced the amazing fi nding that the overexpression 
of a selection of transcription factors, specifi cally those 
characteristic of embryonic cells, could make an adult cell go 
back to an embryonic state.8 The success rate was extremely 
small, being about one in 10,000 cells or less. Nevertheless, 
if this one cell was selected and grown in the laboratory, it 
and its daughters had the characteristics of an ESC. It was 
almost immediately seen that this fi nding had enormous 
possibilities. First, it would be possible to take cells from an 
adult animal or human and derive from them cells having 
the characteristics of ESCs as described above. Second, it 
was realised that if it is possible to derive growing cells from 
the diseased cells of a patient, these cells could be cultured 
in the laboratory and tested for any number of drugs that 
might arrest or even reverse the diseased state. Since it is 
not ethical to test new drugs on living humans, this would 
make it possible to test drugs with cultured somatic cells in 
the laboratory and so screen them for their potential value in 
therapeutic treatment.
The discovery of Takahashi and Yamanaka precipitated a 
tidal wave of activity in this fi eld. Once the technique had 
been demonstrated, it proved very simple to grow these cells 
and to try to improve the effi ciency with which the induced 
pluripotency worked. In fact, there must now be thousands 
of institutes across the world set up under the heading of 
‘regenerative medicine’ using the induced pluripotency 
procedure. As a result, the effi ciency with which these ESC-
like cells can be derived from animal and human tissues 
has improved. Nevertheless, the process is still surprisingly 
ineffi cient, since some 99% of cells, for some reason, do not 
respond to the overexpression of the known factors. It is 
actually rather surprising that the mechanism of action of 
this overexpression procedure is still obscure. That does not, 
however, prevent it from being extremely useful. 
A great deal of work, particularly in the commercial sector, is 
going ahead to try to identify drugs that can alleviate human 
disorders, especially those involving neurodegeneration. The 
problem here is to know whether the cells in culture derived 
from a patient truly represent the disease. It could be that 
several different cell types have to undergo some change for 
the disease to affect a human; if so, it will be very diffi cult to 
truly represent the disease in culture. There is also concern 
that the cells derived by induced pluripotency may themselves 
not truly represent the disease; it is known that, the longer 
you culture cells in the laboratory, the greater the chance of 
genetic changes taking place. There are continuing efforts to 
try to characterise the derived pluripotency cells so that they 
accurately represent the desired cell type for replacement and 
can be safely transplanted to a patient. There is a view that the 
reprogramming induced by eggs, as described above, could 
ultimately be the best route. After all, the egg is provided 
with natural substances that are extremely effective in 
reprogramming sperm, a highly differentiated cell type. There 
is therefore a desire to understand how the egg reprogramming 
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substances work, in order to use them in combination with 
induced pluripotency and provide the best possible cells for 
therapeutic replacement. 
Replacement cell therapy
Recently there has been great success in obtaining cells that 
can alleviate the common human condition referred to as age-
related macular degeneration. In this state, people gradually 
lose peripheral vision and eventually central vision, becoming 
blind, as a result of the death of cells called retinal pigmented 
epithelium cells. These cells provide essential support for the 
photoreceptor cells, absorbing harmful photoreceptor products. 
Retinal pigmented epithelium cells can be derived from human 
ESCs or indeed from human skin cells by induced pluripotency. 
Several companies and laboratories have been actively engaged 
in producing the required retinal pigmented epithelium cells. 
These cells can be grown in culture and then eventually plated 
as a monolayer on a thin plastic sheet. This sheet of cells can 
then be transplanted into the eye of a patient. It now seems 
that the replacement retinal pigmented epithelium cells can 
arrest the deterioration of vision and possibly even improve 
vision from a diseased state. The surgical treatment required 
is very mild; no more complicated than a cataract operation. 
When in full use, it should then be possible for a patient to go 
into an appropriate hospital or treatment centre and receive 
the replacement cells as an outpatient. Animal tests have 
been successful9,10 and permission has just been given for this 
treatment to be tested in humans in UK.
One might ask why this fi rst therapeutic use of replacement 
cells should be applied to the eye. The answer seems to be that 
the absolute number of cells needed to provide new retinal 
pigmented epithelium is quite small, about 5×104 – far below 
what would be needed to replace part, for example, of a heart. 
A major heart infarction can kill over 1011 cells; it would be a 
forbidding task to grow this number of cells in a laboratory, 
so that they retain their desired characteristics and do not 
become cancerous. However, once the transplantation of retinal 
pigmented epithelium proves successful it could well be made 
available to the public at a cost comparable to that of cataract 
treatment. This cost would be considerably less than the annual 
cost of supporting a blind person to carry out their activities. 
It would be expensive to derive these retinal pigmented 
epithelium cells from each patient so that they are given back 
their own genetically compatible cells; however, the eye is an 
immunologically privileged site and it is possible that a patient 
could accept cells from a genetically unrelated source.
Wider issues
Regulatory bodies and lawyers
Before a new procedure can be tested on patients, most 
countries, including UK and USA, require that regulatory 
bodies approve the procedure. This is in order to avoid 
patients suffering from insuffi ciently tested new procedures. 
Unfortunately many such bodies have become extremely 
conservative and take an enormous time, and require extensive 
testing, before they give their approval for a procedure to be 
used on patients. In the particular case of the alleviation of 
macular degeneration of the eye, there has been massive delay 
in approval for this procedure to be tested on patients. When 
I mention this work to general audiences, I am amazed how 
many people say that they would love to have this procedure 
and, even if there is an element of risk, would willingly set aside 
their legal rights in order to have the opportunity of saving 
their vision from further deterioration. Even if, eventually, 
there was some problem with the treatment, the prospect of 
several extra years of life with vision is immensely attractive. 
I would very much hope that regulatory bodies can accelerate 
their procedures and approve procedures much more rapidly 
than at present. 
A major problem that regulatory bodies have is that they are 
threatened by the ability of a judge to award punitive damages if 
the procedure is not wholly successful. Furthermore, I am told 
that the legal profession is extremely reluctant to allow a patient 
to set aside their legal rights on the grounds that the patient 
may not be fully informed about the procedure. I feel very 
strongly that a patient should be allowed to opt for a procedure, 
assuming that it has been explained to them, as far as possible, 
what the procedure involves and what risks might accompany 
the treatment, even if regulatory bodies have not fi nished their 
prolonged deliberations.
The value of basic research
It is interesting, now, to appreciate that this fi eld of cell 
replacement could be seen to have originated in a basic science 
laboratory for purely scientifi c reasons. When decades ago 
we sought to fi nd out whether all cells of the body have the 
same genome, there was no prospect at that time that this could 
have any therapeutic value. Most particularly, the discovery 
of permanently replicating ESCs was crucial to the idea that 
reprogrammed cells could be useful to a patient. Increasingly, 
we fi nd that those applying for research grants have to state 
quite clearly in what respect the work they do will be benefi cial 
to human health. Had this been the case when I started my 
work in the 1950s, the grant support I applied for might not 
have been given. The earliest frog nuclear transfer experiments 
were undertaken in 1952 and it was another 54 years before the 
human health relevance became clearly evident in 2006.
Most of us, as scientists, believe that any basic research project 
that is designed to answer a fundamental question in the fi eld of 
cell biology and development is worth supporting, even if at the 
time its application is not evident.11 ■
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